These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 16570701)

  • 41. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
    Blondeau JM; Borsos S; Hesje CK
    J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
    Watanabe S; Ito T; Hiramatsu K
    J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Pawlak J; Johnson LB
    J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
    Low DE; Nadler HL
    J Antimicrob Chemother; 1997 May; 39 Suppl A():53-8. PubMed ID: 9511063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Yu XH; Song XJ; Cai Y; Liang BB; Lin DF; Wang R
    J Antibiot (Tokyo); 2010 Nov; 63(11):657-9. PubMed ID: 20877368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
    Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
    Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An antibacterial hydroxy fusidic acid analogue from Acremonium crotocinigenum.
    Evans L; Hedger JN; Brayford D; Stavri M; Smith E; O'Donnell G; Gray AI; Griffith GW; Gibbons S
    Phytochemistry; 2006 Oct; 67(19):2110-4. PubMed ID: 16930645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus.
    Moorhouse EC; Mulvihill TE; Jones L; Mooney D; Falkiner FR; Keane CT
    J Antimicrob Chemother; 1985 Mar; 15(3):291-5. PubMed ID: 3158632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
    Farrell DJ; Turner LL; Castanheira M; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
    Lawrence KR; Golik MV; Davidson L
    Am J Ther; 2009; 16(4):333-8. PubMed ID: 19617720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.
    O'Neill AJ; Cove JH; Chopra I
    J Antimicrob Chemother; 2001 May; 47(5):647-50. PubMed ID: 11328777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.